Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous…
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous…
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…
Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in…
IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging funct…
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billio…
ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201…
Der erste Patient in Deutschland wurde im Rahmen der Immatics‘ ACTengine® IMA202-101 Studie behandelt Die deutsche Zulas…
First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trial German regulatory agency, Paul-Ehrlic…
. Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to st…
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-c…